Artificial Intelligence

While quantum computers remain in their infancy, AI could provide a bridge to unlocking their potential.

The U.S. Copyright Office has concluded that existing copyright legislation and principles are well-suited for the issue of AI outputs’ copyrightability.

Artificial intelligence (AI) is increasingly being integrated into health care operations, from administrative functions such as scheduling and billing to clinical decision-making, including diagnosis and treatment recommendations. Although AI offers significant benefits, concerns regarding bias, transparency, and accountability have prompted regulatory responses.

On January 16, 2025, President Joe Biden signed the “Executive Order on Strengthening and Promoting Innovation in the Nation’s Cybersecurity.”

President Donald Trump’s revocation signals a preference for less regulation of the artificial intelligence ecosystem.

Fiduciaries should be aware of recent developments involving AI, including emerging and recent state law changes, increased state and federal government interest in regulating AI, and the role of AI in ERISA litigation.

On January 6, 2025, the U.S. Food and Drug Administration released draft guidance titled Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products explaining the types of information that the agency may seek during drug evaluation.

As AI agents become the next frontier of machine learning, legal frameworks are being developed to guide their responsible deployment.

Our team analyzes the trends impacting companies utilizing artificial intelligence for drug discovery.